Aflibercept versus Ranibizumab as a Second Line Therapy After Bevacizumab for Diabetic Macular Edema

Aflibercept versus Ranibizumab as a Second Line Therapy After Bevacizumab for Diabetic Macular Edema

Nasser G Alsaedi,1,2 Ruba M Alselaimy,3 Abdulaziz A Alshamrani,1 Muhammed AlAjmi,4 Rajiv Khandekar,1 Hassan Al-Dhibi,1 Abdulelah A Al-Abdullah1 1King Khaled Eye Specialist Hospital, Riyadh, Saudi Arabia; 2King Abdullah Medical City, Makkah, Saudi Arabia; 3College of Medicine, King Saud University, R...

Full description

Saved in:
Bibliographic Details
Main Authors: Alsaedi NG, Alselaimy RM, Alshamrani AA, AlAjmi M, Khandekar R, Al-Dhibi H, Al-Abdullah AA
Format: article
Language:EN
Published: Dove Medical Press 2021
Subjects:
aflibercept
bevacizumab
persistent dme
ranibizumab
vegf switch
vascular endothelial growth factor
Ophthalmology
RE1-994
Online Access:https://doaj.org/article/6c17e55774c24a50b1c2e43f1d1e0882
Tags: Add Tag
No Tags, Be the first to tag this record!

Internet

https://doaj.org/article/6c17e55774c24a50b1c2e43f1d1e0882

Similar Items